ArticleBMJ open2026
Can early
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe introduction of immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors has improved outcomes in metastatic clear cell renal cell carcinoma (ccRCC). However, conventional imaging modalities often lack efficacy for response evaluation, facing challenges such as pseudo-progression, mixed responses or delayed responses. Prostate-specific membrane antigen (PSMA) is expressed in the neovasculature of ccRCC, suggesting that PSMA-targeted positron emission tomography (PET) imaging may serve as an early biomarker of treatment efficacy.
methodsPSMA-RENAL is a prospective, multicentre, phase II trial enrolling patients with histologically confirmed metastatic ccRCC and PSMA-positive lesions. Patients will undergo ANALYSIS: This study is the first to evaluate whether early changes in PSMA-PET imaging can predict outcomes in patients with metastatic ccRCC receiving systemic therapy. Early identification of responders may allow timely therapeutic adjustments, potentially enhancing patient outcomes and optimising healthcare resource allocation. ETHICS AND DISSEMINATION: The protocol has received ethical approval. All participants will provide written informed consent. TRIAL REGISTRATION NUMBER: Trial Registration: EU reference number (CTIS): 2024-517098-26-00.Protocol code: PSMA-RENAL.Trial Phase: Therapeutic exploratory (Phase II).Date of registration: March 2025. Currently recruiting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.